261 related articles for article (PubMed ID: 31844890)
1. A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).
Cloughesy TF; Brenner A; de Groot JF; Butowski NA; Zach L; Campian JL; Ellingson BM; Freedman LS; Cohen YC; Lowenton-Spier N; Rachmilewitz Minei T; Fain Shmueli S; ; Wen PY
Neuro Oncol; 2020 May; 22(5):705-717. PubMed ID: 31844890
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study.
Brenner AJ; Peters KB; Vredenburgh J; Bokstein F; Blumenthal DT; Yust-Katz S; Peretz I; Oberman B; Freedman LS; Ellingson BM; Cloughesy TF; Sher N; Cohen YC; Lowenton-Spier N; Rachmilewitz Minei T; Yakov N; Mendel I; Breitbart E; Wen PY
Neuro Oncol; 2020 May; 22(5):694-704. PubMed ID: 31844886
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
Field KM; Simes J; Nowak AK; Cher L; Wheeler H; Hovey EJ; Brown CS; Barnes EH; Sawkins K; Livingstone A; Freilich R; Phal PM; Fitt G; ; Rosenthal MA
Neuro Oncol; 2015 Nov; 17(11):1504-13. PubMed ID: 26130744
[TBL] [Abstract][Full Text] [Related]
4. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
Lee EQ; Reardon DA; Schiff D; Drappatz J; Muzikansky A; Grimm SA; Norden AD; Nayak L; Beroukhim R; Rinne ML; Chi AS; Batchelor TT; Hempfling K; McCluskey C; Smith KH; Gaffey SC; Wrigley B; Ligon KL; Raizer JJ; Wen PY
Neuro Oncol; 2015 Jun; 17(6):862-7. PubMed ID: 25572329
[TBL] [Abstract][Full Text] [Related]
6. Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).
Arend RC; Monk BJ; Shapira-Frommer R; Haggerty AF; Alvarez EA; Amit A; Alvarez Secord A; Muller C; Casado Herraez A; Herzog TJ; Tewari KS; Cohen JG; Huang M; Yachnin A; Holeman LL; Ledermann JA; Rachmilewitz Minei T; Buyse M; Fain Shmueli S; Lavi M; Harats D; Penson RT;
J Clin Oncol; 2024 Jan; 42(2):170-179. PubMed ID: 37906726
[TBL] [Abstract][Full Text] [Related]
7. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.
Nayak L; Molinaro AM; Peters K; Clarke JL; Jordan JT; de Groot J; Nghiemphu L; Kaley T; Colman H; McCluskey C; Gaffey S; Smith TR; Cote DJ; Severgnini M; Yearley JH; Zhao Q; Blumenschein WM; Duda DG; Muzikansky A; Jain RK; Wen PY; Reardon DA
Clin Cancer Res; 2021 Feb; 27(4):1048-1057. PubMed ID: 33199490
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.
Galanis E; Anderson SK; Twohy EL; Carrero XW; Dixon JG; Tran DD; Jeyapalan SA; Anderson DM; Kaufmann TJ; Feathers RW; Giannini C; Buckner JC; Anastasiadis PZ; Schiff D
Cancer; 2019 Nov; 125(21):3790-3800. PubMed ID: 31290996
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.
Weathers SP; Han X; Liu DD; Conrad CA; Gilbert MR; Loghin ME; O'Brien BJ; Penas-Prado M; Puduvalli VK; Tremont-Lukats I; Colen RR; Yung WKA; de Groot JF
J Neurooncol; 2016 Sep; 129(3):487-494. PubMed ID: 27406589
[TBL] [Abstract][Full Text] [Related]
10. NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma.
Lee EQ; Zhang P; Wen PY; Gerstner ER; Reardon DA; Aldape KD; deGroot JF; Pan E; Raizer JJ; Kim LJ; Chmura SJ; Robins HI; Connelly JM; Battiste JD; Villano JL; Wagle N; Merrell RT; Wendland MM; Mehta MP
Cancer; 2020 Jun; 126(12):2821-2828. PubMed ID: 32154928
[TBL] [Abstract][Full Text] [Related]
11. Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma.
Ellingson BM; Patel K; Wang C; Raymond C; Brenner A; de Groot JF; Butowski NA; Zach L; Campian JL; Schlossman J; Rizvi S; Cohen YC; Lowenton-Spier N; Minei TR; Shmueli SF; Wen PY; Cloughesy TF
Neurooncol Adv; 2021; 3(1):vdab082. PubMed ID: 34377989
[TBL] [Abstract][Full Text] [Related]
12. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
Reardon DA; Brandes AA; Omuro A; Mulholland P; Lim M; Wick A; Baehring J; Ahluwalia MS; Roth P; Bähr O; Phuphanich S; Sepulveda JM; De Souza P; Sahebjam S; Carleton M; Tatsuoka K; Taitt C; Zwirtes R; Sampson J; Weller M
JAMA Oncol; 2020 Jul; 6(7):1003-1010. PubMed ID: 32437507
[TBL] [Abstract][Full Text] [Related]
13. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.
Huang RY; Rahman R; Ballman KV; Felten SJ; Anderson SK; Ellingson BM; Nayak L; Lee EQ; Abrey LE; Galanis E; Reardon DA; Pope WB; Cloughesy TF; Wen PY
Clin Cancer Res; 2016 Feb; 22(3):575-81. PubMed ID: 26490307
[TBL] [Abstract][Full Text] [Related]
14. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
Brandes AA; Gil-Gil M; Saran F; Carpentier AF; Nowak AK; Mason W; Zagonel V; Dubois F; Finocchiaro G; Fountzilas G; Cernea DM; Chinot O; Anghel R; Ghiringhelli F; Beauchesne P; Lombardi G; Franceschi E; Makrutzki M; Mpofu C; Urban HJ; Pichler J
Oncologist; 2019 Apr; 24(4):521-528. PubMed ID: 30266892
[TBL] [Abstract][Full Text] [Related]
15. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.
Sandmann T; Bourgon R; Garcia J; Li C; Cloughesy T; Chinot OL; Wick W; Nishikawa R; Mason W; Henriksson R; Saran F; Lai A; Moore N; Kharbanda S; Peale F; Hegde P; Abrey LE; Phillips HS; Bais C
J Clin Oncol; 2015 Sep; 33(25):2735-44. PubMed ID: 26124478
[TBL] [Abstract][Full Text] [Related]
16. VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial.
Coffman-D'Annibale K; Myojin Y; Monge C; Xie C; Hrones DM; Wood BJ; Levy EB; Kleiner D; Figg WD; Steinberg SM; Redd B; Greten TF
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38184304
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent efficacy of bevacizumab in recurrent glioblastoma.
Melhem JM; Tahir A; Calabrese E; Granovskaya I; Atenafu EG; Sahgal A; Lim-Fat MJ; Perry JR
J Neurooncol; 2023 Feb; 161(3):633-641. PubMed ID: 36749445
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of recurrent glioblastoma with single-agent bevacizumab].
Sinkó D; Nemeskéri C
Orv Hetil; 2016 Mar; 157(13):500-3. PubMed ID: 26996897
[TBL] [Abstract][Full Text] [Related]
19. NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.
Tsien CI; Pugh SL; Dicker AP; Raizer JJ; Matuszak MM; Lallana EC; Huang J; Algan O; Deb N; Portelance L; Villano JL; Hamm JT; Oh KS; Ali AN; Kim MM; Lindhorst SM; Mehta MP
J Clin Oncol; 2023 Feb; 41(6):1285-1295. PubMed ID: 36260832
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes with bevacizumab-containing and non-bevacizumab-containing regimens in patients with recurrent glioblastoma from US community practices.
Chen C; Ravelo A; Yu E; Dhanda R; Schnadig I
J Neurooncol; 2015 May; 122(3):595-605. PubMed ID: 25773061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
